SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is currently trending due to a surge in social dominance and trading volume, driven by renewed interest in its quantum-resistant technology and strategic positioning in the US market. The community is actively discussing the coin's perceived undervaluation, potential for a long-term breakout, and recent network activity, with many retail investors debating the timing of a reversal from recent lows.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvell Technology is currently seeing heavy trading volume and heightened investor interest following a partnership announcement with NVIDIA, which includes a multi-billion dollar strategic investment aimed at scaling AI infrastructure. While bullish participants point to the company's central role in the AI supply chain and potential for sustained revenue growth, others are closely watching key technical resistance levels around the $100 mark and navigating significant volatility driven by options flow and broader market uncertainty.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

Kendu is generating intense community engagement as holders focus on its identity as a permissionless brand that incentivizes real-world product development and grassroots marketing. Supporters are actively showcasing their conviction by organizing in-person events and launching diverse initiatives, positioning the project as a long-term, community-driven play.

Amprius Technologies, Inc. engages in the development, manufacture, and market of lithium-ion batteries for mobility applications, including the aviation, electric vehicle and light electric vehicle industries. It operates through the following geographical segments: North America, EMEA, and Asia Pacific. The company was founded by Mark C. Platshon in 2008 and headquartered in Fremont, CA.

Amprius Technologies Inc

Amprius Technologies is trending as investors react to strong quarterly earnings, where the company reported significant year-over-year revenue growth and increased its 2026 revenue guidance. The community is actively discussing the company's expanding customer base and potential for long-term growth as a key battery supplier within the drone and defense sectors, while also debating the stock's volatility and the impact of upcoming warrant triggers.

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals is trending as the community speculates on a potential buyout, particularly by Incyte, driven by the strong commercial trajectory of its FDA-approved drugs Revuforj and Niktimvo. Investors are closely watching for clinical data updates at the upcoming ASH meeting, with many debating the competitive landscape versus Kura Oncology while viewing the stock as significantly undervalued relative to its oncology peers.

Abacus Global Management, Inc. is a pioneering alternative asset manager specializing in uncorrelated financial products that leverage proprietary longevity data and actuarial technology. It operates through the following business segments: Asset Management, Life Solutions and Technology Services. The Asset Management segment provides asset management services primarily to institutional investors, as well as private clients, investing in uncorrelated longevity-based assets, fixed-income replacement strategies, and free cash flow–based investment solutions. The Life Solutions segment is engaged in the buying, selling, and trading of policies, as well as maintaining policies until the receipt of death benefits. The Technology Services segment provides real-time mortality verification, missing participant verification, and other life insurance–specific services to customers on a contract basis. The company was founded by Matthew Ganovsky, Kevin Scott Kirby, and Todd Sean McNealy in 2004 and is headquartered in Orlando, FL.

Abacus Global Management Inc. - Ordinary Shares - Class A

Abacus Global Management is capturing investor attention as its vertical integration strategy, highlighted by a major strategic stake in Manning & Napier, signals a push to control both the origination and distribution of wealth and insurance solutions. While the stock has seen significant momentum, community discussion is currently polarized between those bullish on the company's record growth and platform scalability and those concerned by recent price volatility and technical trading pressures.

LightPath Technologies, Inc. engages in the design, development, manufacture, and distribution of optical and infrared components. Its products include molded glass and assemblies, infrared molded lenses, diamond turned, conventional ground and polished ground lenses and assemblies, and collimator assemblies, which are used in applications involving light detection and ranging technology. The firm supports a range of customers in the field of industrial, laser, defense, medical, telecommunications, and instrumentation. The company was founded in1985 and is headquartered in Orlando, FL.

Lightpath Technologies, Inc. - Ordinary Shares - Class A

Lightpath Technologies is trending as investors monitor ongoing institutional supply absorption and potential contract catalysts, particularly related to the Next-Generation Short-Range Interceptor program. The community is actively debating the impact of recent selling by North Run Strategies while maintaining bullish conviction on the company's long-term positioning as a domestic supplier of critical infrared optics for defense and aerospace.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending following a massive surge in March delivery numbers that significantly beat growth expectations, fueling strong community excitement for potential profitability. Investors are actively discussing the company's multi-brand expansion and the potential for a short squeeze as the stock continues to test key resistance levels.

Palladyne AI Corp. engages in the design, development, and manufacture of industrial robotic systems that augment human performance by combining human intelligence, instinct, and judgment with the strength, endurance, and precision of machines to enhance employee safety and productivity. Its products include Palldyne IQ and Palladyne Pilot. The company was founded by Fraser M. Smith and Benjamin G. Wolff in 2015 and is headquartered in Salt Lake City, UT.

Palladyne AI Corp.

Palladyne AI is currently trending as investors weigh significant revenue growth guidance and the securing of strategic defense contracts for missile propulsion and autonomous swarm technology. While long-term supporters point to the firm's role in critical defense infrastructure, the community remains divided, with active discussions focused on the potential for a short squeeze driven by heavy short interest and the stock's recent high-volume volatility.

Dave, Inc. is a digital banking service. Its products include a budgeting tool to help members manage their upcoming bills to avoid overspending, cash advances through its flagship ExtraCash product to help members avoid punitive overdraft fees, a Side Hustle product, where Dave helps connect members with supplemental work opportunities, and Dave Banking, a modern checking account experience with valuable tools for building long-term financial health. The company was founded by Jason Wilk, Paras Chitrakar, and John Wolanin in October 2015 and is headquartered in Los Angeles, CA.

Dave Inc - Ordinary Shares - Class A

Dave Inc. is trending as investors weigh strong operational performance and share buyback initiatives against technical volatility and concerns regarding potential regulatory oversight. The community remains divided, with many highlighting the stock's operating leverage and growth potential, while others express caution due to ongoing legal developments and broader sector-wide sensitivity to credit regulations.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

TuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update TuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and...

TuHURA Biosciences (NASDAQ:HURA) Releases Earnings Results, Beats Expectations By $0.02 EPS

TuHURA Biosciences (NASDAQ:HURA - Get Free Report) announced its quarterly earnings results on Tuesday. The company reported ($0.10) earnings per share for the quarter, topping analysts' consensus...

TuHURA Biosciences (NASDAQ:HURA) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen upgraded shares of TuHURA Biosciences from a "sell" rating to a "hold" rating in a research report on Monday...

Craig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related Cancers

Craig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related Cancers Craig Tendler, M.D., JNJ's Former...

TuHURA Biosciences (NASDAQ:HURA) Rating Lowered to "Sell" at Wall Street Zen

Wall Street Zen downgraded shares of TuHURA Biosciences from a "hold" rating to a "sell" rating in a research note on Sunday...

TuHURA Biosciences (HURA) Expected to Release Quarterly Earnings on Thursday

TuHURA Biosciences (NASDAQ:HURA) will be releasing earnings before the market opens on Thursday, March 26. (View Earnings Report at...

TuHURA Biosciences (NASDAQ:HURA) Trading Down 3.1% - Here's Why

TuHURA Biosciences (NASDAQ:HURA) Stock Price Down 3.1% - What's Next...

Wall Street Zen Upgrades TuHURA Biosciences (NASDAQ:HURA) to "Hold"

Wall Street Zen upgraded TuHURA Biosciences from a "sell" rating to a "hold" rating in a research note on Saturday...

TuHURA Biosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement

TuHURA Biosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement TuHURA Biosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement PR Newswire TAMPA, Fla., Feb. 27, 2026...

TuHURA Biosciences Announces Participation in Upcoming Investor Conferences

TuHURA Biosciences Announces Participation in Upcoming Investor Conferences TuHURA Biosciences Announces Participation in Upcoming Investor Conferences PR Newswire TAMPA, Fla., Feb. 24, 2026 TAMPA...

This account has been verified as an official HURA representative.

Verified Account

Tu HURA IR

TuHURA Biosciences, Inc. is a clinical-stage immuno-oncology company, which engages in the development of novel technologies to overcome resistance to cancer immunotherapy. The firm’s lead product candidate, IFx2.0, is an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. The company was founded on May 4, 2023 and is headquartered in Tampa, FL.

TuHURA Biosciences Inc.

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$0.12	--	--	N/A
Q4 '25	-$0.12	--	--	N/A
Q3 '25	-$0.14	-$0.14	2.33%	BEAT
Q2 '25	-$0.19	-$0.21	-12.50%	MISSED
Q1 '25	-$0.13	--	--	N/A

HURA
TuHURA Biosciences Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '26

Historical Earnings

Latest HURA News

HURATuHURA Biosciences Inc.